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OBJECTIVE: In this study, we aimed to compare the cardiovascular risk factors that might be associated with
inflammation, atherosclerosis and metabolic syndrome between hemodialysis and peritoneal dialysis patients.
METHODS: Fifty hemodialysis and 50 peritoneal dialysis patients who had been receiving dialysis therapy for at
least one year were included in the study. Venous blood samples were taken after 12 hours of fasting, and
serum glucose, triglyceride, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol,
C-reactive protein, fibrinogen and homocysteine levels were measured. The presence of atherosclerotic plaques in
the carotid artery was evaluated by carotid Doppler ultrasound. These data were analyzed by Student’s t test, the
chi-square test and the Mann-Whitney U test, as appropriate.
RESULTS: No difference was found between the hemodialysis (n=50) and peritoneal dialysis (n=50) patient
groups regarding mean age, gender distribution, body mass index or dialysis duration (p=0.269, 0.683, 0.426,
and 0.052, respectively). LDL-cholesterol, fibrinogen and homocysteine levels were significantly higher in
peritoneal dialysis patients (p=0.006, 0.001, and 0.002, respectively). In patients with diabetes mellitus (n=17)
who were undergoing renal replacement therapy, LDL-cholesterol and fibrinogen levels were significantly
higher than in patients without diabetes mellitus who were undergoing renal replacement therapy (p=0.001
and 0.004, respectively).
CONCLUSION: In our study, cardiovascular risk factors (especially LDL-cholesterol) were more frequent in
peritoneal dialysis patients than in hemodialysis patients.
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’ INTRODUCTION
The incidence of cardiovascular disease is approximately
25-65% in patients with chronic kidney disease, and it may
increase 20- to 40-fold in dialysis patients compared with the
healthy population (1). Several factors increase the risk of
cardiovascular disease in dialysis patients. Modifiable factors
such as anemia, mineral metabolism disorders, uncontrolled
arterial blood pressure, hyperinsulinemia, lipid profile
changes, oxidative stress and inflammation contribute to
the development of cardiovascular disease beyond non-
modifiable factors such as age, gender and genetics (2).
Cardiovascular disease is the main cause of death in
dialysis patients (3). The rate of death due to cardiovascular
disease reaches 40-50% in patients receiving renal replace-
ment therapies (4). Several studies have showed that
peritoneal dialysis patients were more at risk for the
development of dyslipidemia and hyperinsulinemia (5,6).
Glucose-based dialysate use causes the absorption of glucose
at 100-200 g/day (320-640 kcal/day) in patients receiving
peritoneal dialysis. In peritoneal dialysis patients, weight gain
occurs in the first year of the therapy, and the use of glucose-
based solutions might contribute to this condition (7).
Increased body fat mass, lipid profile disorders and
hyperinsulinemia frequently develop in peritoneal dialysis
patients, and the risk of these patients developing cardio-
metabolic syndrome is higher than that of hemodialysis
patients (8). For renal replacement therapies, the effects of
inflammation and increased oxidative stress on the develop-
ment of cardiovascular disease have also been shown.
Elevated homocysteine levels, high circulating fibrinogen
levels, dyslipidemia, an increased body mass index, high
C-reactive protein (CRP) levels and malnutrition mightDOI: 10.6061/clinics/2015(09)01
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increase the risk of cardiovascular disease in dialysis
patients. Insulin resistance, and thus hyperinsulinemia, is
considered to be another causative factor for cardiovascular
disease in end-stage renal disease (ESRD) (3,9).
The present study aimed to compare the cardiovascular
risk factors that might be associated with inflammation,
atherosclerosis and metabolic syndrome between hemodia-
lysis and peritoneal dialysis patients.
’ MATERIALS AND METHODS
Fifty hemodialysis patients (26 males and 24 females) and
50 peritoneal dialysis patients (23 males and 27 females) aged
between 18 and 75 years were included in this study. All
patients had been receiving dialysis therapy at our center for
at least one year without interruption, and their dialysis
adequacies were determined. To standardize and homoge-
nize the dialysis therapy groups, the above-mentioned
dialysis therapies were managed and followed up by the
same team using the same equipment. We excluded patients
who had received dialysis therapy at other centers or who
had not regularly attended the scheduled follow-up visits
during the previous year. Patients with acute infection,
chronic liver disease, collagen tissue disease or malignancy
were excluded from the study.
The ages and genders of the dialysis patients were
recorded. The heights and weights (dry weights) of the
patients were determined by using calibrated height/weight
scales. The body mass index of each patient was calculated
using the formula weight/(height)2. The arterial blood
pressure of the patients was measured three times on both
arms, and the average of the last two measurements was
recorded. A desktop sphygmomanometer (Erkameter 3000
with standard mercury) was used to measure the arterial
blood pressure. To evaluate the biochemical parameters,
venous blood samples were collected after 12 hours of fasting
in the morning and before starting dialysis therapy (hemo-
dialysis or peritoneal dialysis). Serum glucose, triglyceride,
low-density lipoprotein (LDL)-cholesterol, high-density
lipoprotein (HDL)-cholesterol, CRP, fibrinogen and homo-
cysteine levels were measured. Biochemical parameters were
measured using an Abbott Aeroset autoanalyzer (Abbott-
Aeroset System, Germany). CRP was measured using a Delta
SEAC analyzer via the nephelometric method (Radim
Reagent, Italy). Fibrinogen testing was performed with a
Sysmex CA-1500 analyzer (Dade Behring Thrombin Reagent,
Germany) and plasma that was obtained from blood samples
in citrated tubes that were centrifuged at 4000 rpm for
15 minutes. To measure the homocysteine levels, blood
samples collected in EDTA tubes were centrifuged at 4000 rpm
for 15 minutes, without standing time, and the plasma
obtained was studied using an Immulite 1000 analyzer
(Siemens, USA) via the chemiluminescent method. Carotid
Doppler ultrasound of the patients was evaluated using
grayscale and color Doppler ultrasonography with a 7.5-mHz
linear probe (Toshiba Aplio 80). In a semi-dark room, all
subjects lay in the supine position with their necks slightly
hyperextended and rotated away from the imaging transdu-
cer. The carotid intima media thickness (CIMT) was defined
as the distance between the leading edge of the lumen-intima
interface and the leading edge of the media-adventitia
interface of the far wall. The measurements were taken far
from the plaque areas. Three measurements of both carotid
arteries were taken proximal to the carotid bifurcation, from
which the mean CIMT was derived. Standard bicarbonate
dialysates and polysulfone membranes were used in the
hemodialysis patients. The patients received hemodialysis
therapy three times per week; each session lasted four hours.
In the hemodialysis patients, a Kt/V value of 1.4 or more and
a urea reduction ratio (URR) value of 70% or more were
considered to indicate dialysis adequacy. A standard proce-
dure was performed in the peritoneal dialysis patients
(bag changes four times per day, 3x1.36% glucose solutions,
1x3.86% glucose) (Dianeal, Eczacibasi-Baxter, Istanbul, Turkey).
A Kt/V value of 1.7 or more was considered adequate in the
peritoneal dialysis patients. This study was approved by the
ethical committee of the hospital.
Statistical analysis
To analyze the data obtained in this study, NCSS 2007 &
PASS 2008 statistical software (UT, USA) was used. During
the evaluation of study data, Student’s t test was used for
comparisons of parameters between two groups for
descriptive statistical measures (mean, standard deviation,
and frequency) and for quantitative data. The chi-square
test was used to compare qualitative data. The results
were evaluated within a 95% confidence interval and at
a significance level of po0.05. The Mann-Whitney U test
was used to compare parameters without a normal
distribution between two groups. The results were evalu-
ated within a 95% confidence interval and at a significance
level of po0.05.
’ RESULTS
A total of 100 patients (50 hemodialysis and 50 peritoneal
dialysis patients) who were regularly followed up for more
than one year were included in this study. Table 1 shows the
demographic characteristics of the patient groups (Table 1).
No significant difference was found between the hemodia-
lysis and the peritoneal dialysis patients in terms of age
Table 1 - Demographic Characteristics of Hemodialysis and Peritoneal Dialysis Patients.
Parameter Hemodialysis Patients (n=50) Peritoneal Dialysis Patients (n=50) p-value
+Age (years) 43.00±13.00 46.00±14.00 0.269
++Gender
Female
Male
48.00% (n=24)
52.00% (n=26)
54.00% (n=27)
46.00% (n=23)
0.683
+Body mass index (kg/m2) 24.42±1.56 23.85±2.75 0.426
+Systolic blood pressure (mm/Hg) 111±13.72 120±24.49 0.160
+Diastolic blood pressure (mm/Hg) 73±13.02 76.50±12.25 0.387
+Dialysis duration (months) 24.00±12.00 20.00±8.00 0.052
+ Student’s t test.
++Chi-square test.
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(p=0.269), gender (p=0.683), body mass index (p=0.426),
dialysis duration (p=0.052), systolic blood pressure (p=0.160)
or diastolic blood pressure (p=0.387) (Table 1). No significant
difference was found between the hemodialysis group and
the peritoneal dialysis group regarding the proportion of
patients with diabetes mellitus (10/50 versus 7/50, p40.05)
Fasting blood glucose (p=0.006), LDL-cholesterol (p=0.001),
triglyceride (p=0.001), HDL-cholesterol (p=0.0001), fibrinogen
(p=0.001) and homocysteine (p=0.002) levels were significantly
higher in the peritoneal dialysis patient group compared with
the hemodialysis patient group (Table 2). No significant
differences in triglyceride (p=0.708), HDL-cholesterol
(p=0.631), CRP (p=0.828) or homocysteine (p=0.012) levels
were found between the patients with diabetes mellitus and
without diabetes mellitus who were undergoing renal
replacement therapy via either modality (p40.05) (Table 3).
The mean fasting blood glucose (p=0.001), LDL-cholesterol
(p=0.001) and fibrinogen (p=0.0049) levels of the patients with
diabetes mellitus (n=17) who were undergoing peritoneal
dialysis or hemodialysis were significantly higher than those
of patients without diabetes mellitus who were undergoing
peritoneal dialysis or hemodialysis (po0.05) (Table 3).
’ DISCUSSION
Traditional risk factors and ESRD-related risk factors
contribute to the high prevalence of cardiovascular disease
in dialysis patients (10). Atherosclerosis and chronic inflam-
mation are strongly associated with cardiovascular disease in
patients undergoing long-term dialysis therapy (2). Hemo-
dialysis and peritoneal dialysis are generally associated with
similar long-term survival (11). In studies related to life
expectancy and quality of life, cardiovascular disease risk
was the focus of investigation. The importance of cardiome-
tabolic syndrome and its effects on cardiovascular disease is
a current issue (12). To investigate the risk of cardiovascular
disease in dialysis patients, factors including obesity, lipid
profiles, insulin resistance and markers of inflammation were
compared in dialysis patients by Kam-Too et al. The
frequency of metabolic syndrome was approximately 40%
in hemodialysis patients and approximately 60% in perito-
neal dialysis patients. The authors reported that the
frequency of cardiovascular disease might be higher in
patients with metabolic syndrome (13).
McIntyre et al. noted that the glucose-based solutions used
in peritoneal dialysis could significant contribute to the
development of obesity as well as metabolic syndrome in
peritoneal dialysis patients compared with hemodialysis
patients. Glucose-based solutions used intraperitoneally to
treat peritoneal dialysis patients also had systemic glucotoxic
effects beyond local peritoneal effects. Given that functional
and structural changes occurred in peritoneal membranes
with the use of glucose-based solutions, an elevated
advanced glycation end-product concentration in the skin
of diabetic and non-diabetic peritoneal dialysis patients
parallel to dialysis vintage was shown to be evidence of
systemic glucotoxicity (14).
According to the studies performed regarding the
frequency and significance of cardiometabolic syndrome in
peritoneal dialysis patients, dyslipidemia develops in addi-
tion to weight gain in most patients, especially within the
first year (13,15).
In our study, no difference between the dialysis patient
groups regarding body mass index was observed, but fasting
blood glucose, LDL-cholesterol, triglyceride and HDL-
cholesterol levels were significantly higher in peritoneal
dialysis patients. No significant difference in the rate of
diabetes mellitus was found between the study groups. We
suggested that the higher levels of blood glucose and LDL-
cholesterol in the peritoneal dialysis patients in our study
group might have been due to glucotoxic effects caused by
the glucose-based solutions used and that these levels may
indicate an increased risk of atherosclerosis. These results
were in agreement with those of other studies reporting
Table 2 - Comparison of Clinical and Biochemical Parameters between Hemodialysis and Peritoneal Dialysis Patients.
Parameter Hemodialysis Patients Peritoneal Dialysis Patients p-value
+Fasting blood glucose (mg/dl) 108.00±48.00 136.00±52.00 0.006
+LDL-cholesterol (mg/dl) 91.00±22.30 123.00±37.30 0.001
+Triglyceride (mg/dl) 127.20±18.50 167.40±24.70 0.001
+HDL-cholesterol (mg/dl) 41.30±5.70 33.60±7.90 0.001
+C-reactive protein (mg/dl) 2.16±1.87 2.91±2.00 0.229
+Fibrinogen (IU/ml) 282.53±95.78 402.20±105.21 0.001
+Homocysteine (IU/ml) 10.82±3.74 20.20±11.37 0.002
++Presence of atherosclerotic plaque
in carotid artery
24.00% (n=12) 44.00% (n=22) 0.185
+ Student’s t test.
++Chi-square test.
Table 3 - Biochemical Data of Diabetes Mellitus and Non-Diabetes Mellitus Dialysis Patient Groups.
Biochemical Parameter Diabetes Mellitus (n=17) Non-Diabetes Mellitus (n=83) p-value
Fasting blood glucose (mg/dl) 162.90±36.12 96.39±16.89 0.001
LDL-cholesterol (mg/dl) 131.80±55.91 91.63±28.84 0.001
Triglyceride (mg/dl) 144.34±61.84 167.36±108.57 0.708
HDL-cholesterol (mg/dl) 41.26±12.11 39.90±9.52 0.631
CRP (mg/dl) 2.75±1.91 2.82±2.28 0.828
Homocysteine (IU/ml) 18.90±10.39 13.76±8.74 0.012
Fibrinogen (IU/ml) 395.15±107.67 308.52±107.30 0.004
Mann-Whitney U test: po0.05.
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similar results (5,7). Huang et al. demonstrated that LDL-
cholesterol and apolipoprotein B levels were higher in
peritoneal dialysis patients and concluded that atherosclero-
sis might be more prevalent in these patients (15). The
reduction of LDL-cholesterol and lipoprotein levels in
patients switched from peritoneal dialysis to hemodialysis
also supported the concept that dyslipidemia, and thus
atherosclerosis, may occur more commonly in peritoneal
dialysis patients (16).
In our study, to determine the presence of inflammation
and atherosclerosis in peritoneal dialysis and hemodialysis
patients, we examined homocysteine and fibrinogen levels
and the presence of atherosclerotic plaques in the carotid
artery. In the peritoneal dialysis patient group, plasma
fibrinogen and serum homocysteine levels were significantly
higher, but no difference was found between the two dialysis
groups regarding the presence of atherosclerotic plaques in
the carotid artery.
Several studies have shown the presence of chronic
inflammation in every stage of chronic renal disease, with
inflammation increasing with disease progression (17).
Plasma fibrinogen levels were increased in the presence of
inflammation, and these levels were an important risk factor
for the development of cardiovascular disease. In the current
study, fibrinogen levels were increased with both types of
dialysis therapies. However, different results were obtained
when comparing fibrinogen levels between the hemodialysis
and peritoneal dialysis therapies. The results of certain
studies have shown that fibrinogen levels were higher in
peritoneal dialysis patients when the serum cholesterol and
lipoprotein (a) levels were similar to those in hemodialysis
patients and that this condition was associated with a higher
risk of developing atherosclerosis in peritoneal dialysis
therapy (18).
The reason for elevated fibrinogen levels in peritoneal
dialysis patients remains unclear, but factors such as
peritoneal protein loss and hyperinsulinemia might cause
the increase in this patient group (18,19). Homocysteine
levels are also increased in patients with moderately
impaired renal function. The majority of chronic renal
disease patients have elevated homocysteine levels that are
3- to 4-fold above normal (17). Hyperhomocysteinemia is
considered to be an important risk factor in the development
of atherosclerotic vascular disease (20). Homocysteine levels
are higher in peritoneal dialysis patients, independent of age,
dialysis adequacy, serum B6 levels, and protein catabolic
rates (21). In our study, the elevated homocysteine levels in
peritoneal dialysis patients may support the concept that
peritoneal dialysis patients are at a greater risk for athero-
sclerosis. Peritoneal dialysis solutions that cannot remove
homocysteine from the body might also have contributed to
the elevated homocysteine levels. However, considering that
the effects of the hemodialysis and peritoneal dialysis
modalities on serum homocysteine levels are generally
similar, higher serum homocysteine levels in peritoneal
dialysis patients might be associated with an increased
presence of atherosclerosis.
An increased CIMT and the presence of atherosclerotic
plaques are generally considered to be indicators of
subclinical atherosclerosis. Several studies have shown that
increased levels of LDL and the atherogenic index of plasma
are related to an increased CIMT and the presence of
atherosclerotic plaques. In particular, the atherogenic index
of plasma and the CIMT were increased in dialysis patients
compared with a healthy control group (1). In our study, the
frequency of atherosclerotic plaques was higher in peritoneal
dialysis patients, but the difference was not significant
(p40.05). Thus, we could not evaluate our study parameters
by regression analysis methods.
Our study was a cross-sectional observational study, so we
could not evaluate the cardiovascular complications and/or
mortality rates of our dialysis patients. However, a review of
the data from our dialysis clinic over the past year showed
that only 1 hemodialysis patient (and no peritoneal dialysis
patients) had died. Additionally, three peritoneal dialysis
patients and one hemodialysis patient underwent kidney
transplantation during this period (unpublished data).
Traditional risk factors and ESRD-related risk factors
contribute to the high prevalence of cardiovascular disease
in dialysis patients. Atherosclerosis and chronic inflamma-
tion are strongly associated with cardiovascular disease in
patients undergoing long-term dialysis therapy. Most studies
have shown that peritoneal dialysis patients are at greater
risk for cardiovascular disease and atherosclerosis. In our
study, peritoneal dialysis patients had a significant increase
in cardiovascular risk factors but a non-significant increase in
subclinical atherosclerosis. Further studies are required in
this field.
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